Investigation of early protein changes in the urinary bladder following partial bladder outlet obstruction by proteomic approach

Journal of Korean Medical Science

Volumn 20, Issue 6, 2005, Pages 1000-1005

  Kim, Hyung Jee ^a   Sohng, Inho ^a   Kim, Dong Hee ^a   Lee, Dong Cho ^a   Hwang, Cheol Ho ^a   Park, Ji Young ^a   Ryu, Jin Woo ^b  

^a Dankook University   (South Korea)

^b Choongmu Hospital   (South Korea)

Author keywords

Bladder; Prostatic Hyperplasia; Proteomics; Urethral Obstruction

Indexed keywords

EID: 31544446029     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2005.20.6.1000     Document Type: Article

References (30)

1. Caine M. The present role of alpha-adrenergic blockers in the treatment of benign prostatic hypertrophy. J Urol 1986; 136: 1-4.
2. Abrams PH, Farrar DJ, Turner-Warwick RT, Whiteside CG, Feneley RC. The results of prostatectomy: a symptomatic and urodynamic analysis of 152 patients. J Urol 1979; 121: 640-2.
3. Barry MJ, Meigs JB. The natural history of benign prostatic hyperplasia. In: Lepor H, editor. Prostatic disease. Philadelphia: Saunders 2000; 106-15.
4. Anderson KE. Storage and voiding symptoms: pathophysiologic aspects. Urology 2003; 62: 3-10.
5. Levin RM, Chichester P, Hass MA, Goslin JA, Buttyan R. Obstructive bladder dysfunction: morphological, biochemical and molecular changes. Eur Urol suppl 2002; 1: 14-20.
6. Santarosa R, Colombel MC, Kaplan S, Monson F, Levin RM, Buttyan R. Hyperplasia and apoptosis. Opposing cellular processes that regulate the response of the rabbit bladder to transient outlet obstruction. Lab Invest 1994; 70: 503-10.
7. Chen MW, Krasnapolsky L, Levin RM, Buttyan R. An early molecular response induced by acute overdistension of the rabbit urinary bladder. Mol Cell Biochem 1994; 132: 39-44.
8. Flynn BJ, Mian HS, Cera PJ, Kabler RL, Mowad JJ, Cavanaugh AH, Rothblum LI. Early molecular changes in bladder hypertrophy due to bladder outlet obstruction. Urology 2002; 59: 978-82.
9. Steers WD. Overactive bladder (OAB): What we thought we knew and what we know today. Eur Urol suppl 2002; 1: 3-10.
10. Levin RM, Wein AJ, Buttyan R, Monson FC, Longhurst PA. Update on bladder smooth-muscle physiology. World J Urol 1994; 12: 226-32.
11. Levin RM, Brading AF, Mills IW, Longhust PA. Experimental models of bladder obstruction. In: Lepor H, editor. Prostatic disease. Philadelphia: Saunders 2000; 169-96.
12. Wilkins MR, Sanchez JC, Gooley AA, Appel RD, Humphery-Smith I, Hochstrasser DF, Williams KL. Progress with proteome projects: why all proteins expressed by a genome should be identified and how to do it. Biotechnol Genet Eng Rev 1996; 13: 19-50.
13. Pandey A, Mann M. Proteomics to study genes and genomes. Nature 2000; 405: 837-46.
14. Adam GC, Cravatt BF, Sorensen EJ. Profiling the specific reactivity of the proteome with non-directed activity-based probes. Chem Biol 2001; 8: 81-95.
15. Chambers G, Lawrie L, Cash P, Murray GI. Proteomics: a new approach to the study of disease. J Pathol 2000; 192: 280-8.
16. Katada E, Mitake S, Matsukawa N, Otsuka Y, Tsugu Y, Fujimori O, Ojika K. Distribution of hippocampal cholinergic neurostimulating peptide (HCNP)-like immunoreactivity in organs and tissues of young Wistar rats. Histochem Cell Biol 1996; 105: 43-51.
17. Katada E, Ojika K, Mitake S, Ueda R. Neuronal distribution and subcellular localization of HCNP-like immunoreactivity in rat small intestine. J Neurocytol 2000; 29: 199-207.
18. Ojika K, Ueki Y, Mitake S, Tsugu Y, Otsuka Y, Katada E. Demonstration of the biological activity of peptide fragments related to human and rat hippocampal cholinergic neurostimulating peptide (HCNP). Neurosci Lett 1996; 215: 127-30.
19. Sarfarazi M, Rezaie T. Optineurin in primary open angle glaucoma. Ophthalmol Clin North Am 2003; 16: 529-41.
20. Rezaie T, Child A, Hitchings R, Brice G, Miller L, Coca-Prados M, Heon E, Krupin T, Ritch R, Kreutzer D, Crick RP, Sarfarazi M. Adultonset primary open-angle glaucoma caused by mutations in optineurin. Science 2002; 295: 1077-9.
21. Shapland C, Hsuan JJ, Totty NF, Lawson D. Purification and properties of transgelin: a transformation and shape change sensitive actin-gelling protein. J Cell Biol 1993; 121: 1065-73.
22. Lawson D, Harrison M, Shapland C. Fibroblast transgelin and smooth muscle SM22 alpha are the same protein, the expression of which is down-regulated in many cell lines. Cell Motil Cytoskeleton 1997; 38; 250-7.
23. Zeidan A, Sward K, Nordstrom I, Ekblad E, Zhang JC, Parmacek MS, Hellstrand P. Ablation of SM22alpha decreases contractility and actin contents of mouse vascular smooth muscle. FEBS Lett 2004; 562: 141-6.
24. Stefankova P, Kollarova M, Barak I. Thioredoxin-structural and functional complexity. Gen Physiol Biophys 2005; 24: 3-11.
25. Nakamura H. Thioredoxin and its related molecules: update 2005. Antioxid Redox Signal 2005; 7: 823-8.
26. Lim YK, Jenner A, Ali AB, Wang Y, Hsu SI, Chong SM, Baumman H, Halliwell B, Lim SK. Haptoglobin reduces renal oxidative DNA and tissue damage during phenylhydrazine-induced hemolysis. Kidney Int 2000; 58: 1033-44.
27. Dietz KJ, Horling F, Konig J, Baier M. The function of the chloroplast 2-cysteine peroxiredoxin in peroxide detoxification and its regulation. J Exp Bot 2002; 53: 1321-9.
28. Liu FT, Hsu DK, Zuberi RI, Kuwabara I, Chi EY, Henderson WR Jr. Expression and function of galectin-3, a beta-galactoside-binding lectin, in human monocytes and macrophages. Am J Pathol 1991; 147: 1016-28.
29. Imbe H, Okamoto K, Kadoya T, Horie H, Senba E. Galectin-1 is involved in the potentiation of neuropathic pain in the dorsal horn. Brain Res 2003; 993: 72-83.
30. Stillman BN, Mischel PS, Baum LG. New roles for galectins in brain tumors - from prognostic markers to therapeutic targets. Brain Pathol 2005; 15: 124-32.